Cast:Joel TopfJennie LinSwapnil HiremathMatt SparksSamira FaroukShow Notes:Pathway 2 Trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00257-3/fulltextNephJC discussion of Pathway2http://www.nephjc.com/pathwayThe DIAMOND Trial. Much more ambitious than I described in the podcast.https://clinicaltrials.gov/ct2/show/NCT03888066SPRINThttps://www.nejm.org/doi/full/10.1056/NEJMoa1511939Omron 907 BP cuffonly $678 from Amazon: https://www.amazon.com/Omron-HEM-907XL-IntelliSense-Professional/dp/B000FENZPSEvaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555446/The TOPCAT Trial story: A Clinical Trial Torpedoed By Fraud and Incompetencehttps://blogs.sciencemag.org/pipeline/archives/2017/04/27/a-clinical-trial-torpedoed-by-fraud-and-incompetenceCJSAN article looking at 24-hour urine for calcium and phos with patiromerhttps://cjasn.asnjournals.org/content/14/1/103Swap’s best tweeters of #Kidney Wkaldorodrigo https://twitter.com/aldorodrigoAlex Meraz https://twitter.com/nephroguyJoshua Waitzman https://twitter.com/JwaitzKIDNEYconkidneycon.org

Freely Filtered 009 AMBER

Twice monthly (aspirational) recap of the NephJC journal club. NephJC reviews the most important manuscripts which are driving nephrology forward and improving our understanding of the kidney.

Medicine

Science & Medicine

Science

Health & Fitness

On May 24th, at the ERA meeting in Stockholm Sweden (this will not be the last GLP1ra talk at Stockholm), Vlado Perkovic presented the previously spoiled results of FLOW. In addition to simultaneous publication in the NEJM, it made the front page in newspapers around the world. As one headline writer said, “Is there anything Ozempic can’t do?”

Episode 71: The Spice must FLOW!

Nothing terrifies nephrologists, quite like the consult from labor and delivery. And one of the most vexing questions is, “Is this preeclampsia or proteinuric CKD or a lupus flare?” Perhaps a newly approved blood test will be able to shed light on this clinical conundrum. The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) has appeared predictive of severe preeclampsia. The PRAECIS trial evaluated this is a prospective manner.

Join the filtrate as we do a truly incompetent job discussing this study.

Episode 70: Predicting Preeclampsia, the PRAECIS trial

FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?

Episode 69:DUPLEX Sparsentan, it’s no Acthar Gel

Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something.

No. The answer is no.

But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine.

Stop it. Just stop it.

Join the filtrate as we dissect a recent study looking at this issue with the lead author.

Freely Filtered 68: Inpatient hypertension

NephMadness prides itself on not repeating topics. Most topics don’t get revisited for years after a single appearance. But one region stands alone. One region is making its fourth appearance in the 12 year history of NephMadness! That region is Animal House!

Modern medical education doesn’t go to the comparative physiology well very often. So when we do, it is always fresh and exciting. Join the Filtrate as we explore the fascinating world of the Gila Monster and Mourning Dove.

Freely Filtered 009 AMBER

Download our free app to listen on your phone